Lion Biotechnologies, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), has appointed Molly Henderson, CPA, as chief financial officer, effective immediately.

Previously, Henderson was the chief financial officer of VirtualScopics from 2002 to 2008, and chief business and financial officer and senior vice president from 2008 to 2013. Henderson played a key role in taking VirtuoScopics from an early-stage life science start-up to a publicly traded Nasdaq company, and secured several rounds of funding from both strategic and institutional investors. Henderson was corporate controller for Ultralife and a manager in the audit division of PricewaterhouseCoopers.